SCHEDULE 13G/A: Hudson Bay Capital Management LP and Sander Gerber Disclose 4.99% Stake in Psyence Biomedical Ltd.

Hudson Bay Capital Management LP and Sander Gerber have filed an amended Schedule 13G, reporting a 4.99% beneficial ownership stake in Psyence Biomedical Ltd., primarily through warrants subject to a beneficial ownership blocker.

Summary

• Hudson Bay Capital Management LP and Mr. Sander Gerber (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G.
• The Reporting Persons beneficially own an aggregate of 237,768 common shares of Psyence Biomedical Ltd.
• This ownership represents 4.99% of the company's outstanding common shares.
• The shares are issuable upon the exercise of warrants held by Hudson Bay Master Fund Ltd.
• The warrants are subject to a 4.99% beneficial ownership blocker, meaning the Reporting Persons cannot exercise them if it would result in their beneficial ownership exceeding 4.99% of the outstanding common shares.
• The percentage is calculated based on 4,527,128 common shares of Psyence Biomedical Ltd. reported outstanding as of March 31, 2025.
• Mr. Gerber disclaims beneficial ownership of these securities.

Sentiment

Score: 5

Explanation: Neutral. This is a factual, routine regulatory filing reporting beneficial ownership and does not contain information that would typically sway sentiment positively or negatively regarding the company's operations or financial performance.

Positives

• The filing provides transparency regarding significant institutional ownership in Psyence Biomedical Ltd.

Negatives

• The document does not contain information that would be considered negative regarding the company's operational or financial performance.

Risks

• The beneficial ownership is capped at 4.99% due to a contractual blocker on the warrants, limiting the Reporting Persons' ability to increase their stake beyond this threshold through warrant exercise.

Future Outlook

The document, a Schedule 13G filing, does not provide any forward-looking statements or guidance regarding Psyence Biomedical Ltd.'s future operations or financial performance.

Industry Context

This filing is a routine regulatory disclosure of beneficial ownership by an investment firm and does not provide specific insights into broader industry trends or competitive dynamics within the biomedical sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding the beneficial ownership structure of a significant institutional investor, clarifying the nature and limitations of their stake.

Key Dates

Keywords

Psyence Biomedical Ltd., Hudson Bay Capital Management LP, Sander Gerber, Schedule 13G, beneficial ownership, warrants, common shares, SEC filing, institutional ownership